查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1837439

急性腎損傷治療市場（按治療類型、急性腎損傷類型、最終用戶和患者人口統計）—全球預測，2025-2032 年

Acute Kidney Injury Treatment Market by Treatment Type, AKI Type, End User, Patient Demographics - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年急性腎損傷治療市場將成長至 37.5 億美元，複合年成長率為 8.03%。

主要市場統計數據
基準年2024年 20.2億美元
預計2025年 21.8億美元
預測年份：2032年 37.5億美元
複合年成長率（%） 8.03%

策略介紹，解釋為什麼急性腎損傷治療重點需要協調的臨床創新、診斷精確度和系統層級回應

急性腎衰竭是重症加護、腎臟病學以及更廣泛的醫院系統交叉領域面臨的複雜臨床挑戰。近年來，人們越來越關注早期發現、治療方法最佳化以及連接急診、加護治療和門診追蹤的綜合護理路徑。診斷技術的進步、體外治療的逐步改進以及對藥物治療安全性的日益關注，正在改變臨床決策和醫療保健提供者的工作流程。同時，人口結構的變化，例如人口老化和慢性併發症的增加，正在增加腎損傷風險患者的比例。

本簡介闡述了驅動治療選擇和組織反應的核心動態。它強調了多學科協作的必要性、對更快、更準確的診斷訊號的需求，以及價值觀對治療方法選擇和出院後管理日益成長的影響。透過將臨床趨勢置於衛生系統的優先事項（效率、病人安全和最佳化結果）之中，本刊頭強調了為什麼臨床領導者、製造商和付款人必須圍繞能夠顯著減輕急性腎損傷負擔的創新展開合作，同時關注成本和供應鏈的現實情況。

技術創新、生物標記的進步以及不斷發展的治療模式如何改變急性腎損傷的治療途徑和結果

重塑急性腎損傷治療的變革既基於技術，也基於系統。在技​​術方面，在加護治療環境中採用連續性腎臟替代療法 (CRT) 的同時，設備層面也得到了改進，從而提高了血流動力學耐受性，並促進了與即時監測系統的整合。同時，生物標記研究的進展使得更早的風險分層和更有針對性的干涉措施成為可能，從而減少了對血清肌酸酐的單一依賴。這些技術變革得到了數位平台的增強，這些平台可以匯總生理數據並進行預測分析，從而識別即將面臨風險的患者，並促進更早的臨床回應。

從系統角度來看，醫療服務模式正變得更加分散，更多地利用門診和專科診所進行追蹤和支持性管理。這一趨勢雖然減輕了住院患者的負擔，但也需要新的途徑來確保醫療服務的連續性，尤其是對於那些從醫院轉入家中且仍有殘留腎功能損害的患者。此外，抗生素管理計劃、最大程度減少腎毒素暴露的通訊協定以及標準化的液體管理途徑正在被納入機構實踐，從而改變了急性腎損傷的發生率和嚴重程度。總而言之，這些轉變為能夠提供涵蓋急性期至急性後期診斷、治療和服務解決方案的公司創造了跨部門合作和商業機會。

2025 年美國關稅變化的預期累積效應可能會重塑急性腎損傷採購、供應鏈彈性和醫療服務

美國預計在2025年實施新的和修訂的關稅，這將引發一系列供應側動態，可能對急性腎損傷的治療提供產生重大影響。針對醫療設備、耗材或零件進口的關稅措施可能會增加透析設備、過濾器和一次性耗材的購買成本。這些成本壓力可能會導致採購商重新評估籌資策略，尋找替代供應商，重新協商契約，並可能延長資本密集型設備的使用壽命或推遲更換。此類調整可能會對醫院系統內的臨床排程、醫療模式可用性和資本規劃產生下游影響。

除了直接的價格效應外，政策主導的貿易變化往往會加速在地化趨勢。製造商和供應商可以透過重組供應鏈、將某些職能轉移到國內或尋求關鍵醫療用品的關稅分類或豁免來應對。雖然這些應對措施可以減少長期風險，但隨著新的製造和分銷安排的擴大，它們也會造成短期中斷。同時，醫療保健提供者和衛生系統可能會加大力度，最佳化依賴在地採購藥品和耗材的藥物治療和支持性護理的使用，以對沖進口供應波動。臨床醫生和採購團隊需要合作，以確保醫療服務的連續性，同時應對價格和供應情況的變化。而積極溝通供應保證和替代採購的產業相關人員可能會在這項關稅主導的轉型中獲得競爭優勢。

關鍵細分洞察，將治療方式、損傷病因、治療環境和人口群體與精確的臨床和商業性優先事項進行映射

有效的細分視​​角透過將治療方式、損傷亞型、護理環境和患者群體聯繫起來，明確臨床需求和商業性重點。根據治療類型，市場分為透析、藥物治療和支持性護理。透析進一步分析為持續性腎臟替代療法、間歇性血液透析機及持續性低效透析。藥物治療著重於抗生素、利尿劑、止痛藥和補液藥物，而支持性護理則著重於飲食和液體管理。這種以治療為導向的視角強調了特定於治療方式的設備特性、耗材物流和藥物安全計畫必須與臨床路徑保持一致。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合人工智慧演算法早期發現住院病患急性腎損傷
  • 新興的生物標記指導的個人化治療通訊協定，以降低外科患者急性腎損傷的風險
  • 過渡到加護治療環境中的照護現場診斷設備以快速評估腎功能
  • 開發新的腎臟替代療法，改善生物相容性並減少ICU護理併發症
  • 增加對基於細胞的再生醫學方法的投資，以修復移植後腎損傷的機制
  • 擴展遠距遠端醫療病患監測平台，以便早期療育急性腎損傷的管理
  • SGLT2抑制劑在糖尿病患者腎臟保護和預防急性腎損傷的應用日益增多
  • FDA 和 EMA 加速監管行動，授予創新 AKI 治療候選藥物突破性療法認定

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章急性腎損傷治療市場（依治療類型）

  • 透析
    • 連續性腎臟替代療法（CRRT）
    • 間歇性血液透析機
    • 持續低效透析（SLED）
  • 藥物治療
    • 抗生素
    • 利尿劑
    • 疼痛管理藥物
    • 補液藥物
  • 支持性護理
    • 飲食管理
    • 體液管理

第9章急性腎損傷治療市場-AKI類型

  • 腎內源性急性腎損傷
  • 腎後性急性腎損傷
  • 腎前性急性腎損傷

第 10 章急性腎損傷治療市場（依最終使用者）

  • 門診手術中心
  • 醫院
  • 專科診所

11. 急性腎損傷治療市場（依患者人口統計）

  • 成年患者
  • 老年患者
  • 兒科患者

第12章急性腎損傷治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章急性腎損傷治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 急性腎損傷治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Alloksys Life Sciences BV
    • Amgen Inc.
    • Asahi Kasei Medical Co., Ltd.
    • Astellas Pharma Inc.
    • B. Braun Melsungen AG
    • Baxter International, Inc.
    • Bayer AG
    • bioMerieux SA
    • CardioRenal Systems, Inc.
Product Code: MRR-035DA3C63706

The Acute Kidney Injury Treatment Market is projected to grow by USD 3.75 billion at a CAGR of 8.03% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.02 billion
Estimated Year [2025] USD 2.18 billion
Forecast Year [2032] USD 3.75 billion
CAGR (%) 8.03%

A strategic introduction explaining why acute kidney injury treatment priorities demand coordinated clinical innovation, diagnostic precision, and systems-level responses

Acute kidney injury presents a complex clinical challenge at the intersection of critical care, nephrology, and broader hospital systems. Recent years have seen an intensification of focus on early detection, modality optimization, and integrated care pathways that connect emergency, intensive care, and outpatient follow-up. Advances in diagnostics, incremental improvements in extracorporeal therapy, and heightened attention to medication safety have altered clinical decision-making and provider workflows. At the same time, demographic shifts such as an aging population and rising prevalence of chronic comorbidities increase the proportion of patients at risk for renal insults, which in turn elevates pressure on hospitals and specialty clinics to adopt protocols that reduce progression and long-term morbidity.

This introduction frames the core dynamics driving treatment choices and organizational responses. It highlights the imperative for multidisciplinary coordination, the need for faster and more precise diagnostic signals, and the growing influence of value-based considerations on modality selection and post-discharge management. By situating clinical practice trends within health-system priorities-efficiency, patient safety, and outcome optimization-this opening underscores why clinical leaders, manufacturers, and payers must align around innovations that demonstrably reduce acute kidney injury burden while remaining attentive to cost and supply chain realities.

How technological innovations, biomarker advances, and evolving care models are jointly transforming acute kidney injury treatment pathways and outcomes

Shifts reshaping acute kidney injury care are both technological and systemic. On the technological front, the adoption of continuous renal replacement therapies in intensive care settings has been accompanied by device-level refinements that improve hemodynamic tolerance and facilitate integration with real-time monitoring systems. Parallel advances in biomarker research are enabling earlier risk stratification and more targeted intervention, reducing reliance on serum creatinine alone. These technical changes are reinforced by digital platforms that aggregate physiologic data, enabling predictive analytics to identify patients at imminent risk and prompting earlier clinical responses.

Systemically, care delivery models are moving toward decentralization and greater use of ambulatory and specialty clinic settings for follow-up and supportive management. This trend reduces inpatient burden while necessitating new pathways for continuity of care, particularly for patients who transition from hospital to home with residual kidney dysfunction. Additionally, antibiotic stewardship programs, protocols to minimize exposure to nephrotoxins, and standardized fluid management pathways are becoming embedded in institutional practice, altering the incidence and severity of acute kidney injury episodes. Taken together, these shifts create opportunities for cross-disciplinary collaboration and for companies that can deliver integrated diagnostic, therapeutic, and service solutions that span the acute-to-post-acute continuum.

Projected cumulative effects from United States tariff changes in 2025 that could reshape procurement, supply chain resilience, and treatment delivery for acute kidney injury

The prospect of new or modified tariffs in the United States in 2025 introduces a set of supply-side dynamics that can materially affect acute kidney injury treatment delivery. Tariff measures focused on medical devices, disposables, or component imports can increase acquisition costs for dialysis machines, filters, and single-use consumables, which are integral to both inpatient and ambulatory renal replacement therapy. Such cost pressures may drive purchasers to reassess procurement strategies and to explore alternative suppliers, contract renegotiation, and in some cases, extended use or deferred replacement of capital-intensive equipment. These adjustments can have downstream implications for clinical scheduling, modality availability, and capital planning within hospital systems.

Beyond direct price effects, policy-driven trade changes often accelerate localization trends. Manufacturers and suppliers may respond by reconfiguring supply chains, onshoring certain capabilities, or seeking tariff classifications and exemptions for critical medical goods. Such responses can reduce long-term exposure but also create short-term disruptions as new manufacturing or distribution arrangements scale. In parallel, providers and health systems will likely intensify efforts to optimize the use of pharmacological treatments and supportive care that rely on locally sourced medications and consumables, as a hedge against imported supply volatility. Clinicians and procurement teams will need to coordinate to ensure continuity of care while navigating pricing and availability changes, and industry players that proactively communicate about supply assurance and alternative sourcing will have a competitive advantage during any tariff-driven transition.

Key segmentation insights that map treatment modalities, injury etiologies, care settings, and demographic cohorts to precise clinical and commercial priorities

An effective segmentation lens clarifies clinical needs and commercial priorities by linking treatment modalities, injury subtypes, care settings, and patient cohorts. Based on treatment type, the market is studied across dialysis, pharmacological treatment, and supportive care where dialysis is further analyzed across continuous renal replacement therapy, intermittent hemodialysis, and sustained low-efficiency dialysis; pharmacological treatment considerations encompass antibiotics, diuretics, pain management drugs, and rehydration drugs; and supportive care focuses on dietary management and fluid management. This treatment-oriented view highlights how modality-specific device features, consumable logistics, and medication safety programs must align with the clinical pathway.

Based on AKI type, the analysis differentiates intrinsic renal acute kidney injury, post-renal acute kidney injury, and pre-renal acute kidney injury to surface diagnostic needs and targeted interventions that vary by etiology. Based on end user, the review segments ambulatory surgical centers, hospitals, and specialty clinics to show how engineering requirements, staffing models, and capital deployment differ across settings. Based on patient demographics, attention to adult patients, geriatric patients, and pediatric patients reveals nuances in dosing, device size, and follow-up intensity. Integrating these segmentation axes provides a multidimensional picture in which product design, clinical protocols, and service models must be calibrated to fit distinct combinations of modality, etiology, care setting, and patient age profile.

Regional perspectives on adoption, procurement, and capacity building across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence AKI care pathways

Regional dynamics shape how acute kidney injury treatment innovations are adopted, financed, and scaled. In the Americas, health systems emphasize hospital-based critical care capacity with a growing interest in ambulatory and home-based modalities to alleviate inpatient demand; procurement trends and payer arrangements in this region incentivize device interoperability and total-cost-of-care initiatives. Europe, Middle East & Africa displays heterogeneity, where some markets prioritize centralized specialist centers and others focus on expanding point-of-care capabilities; regulatory diversity across the region drives manufacturers to pursue modular product strategies and regionally tailored clinical evidence to support adoption. In the Asia-Pacific region, rapid expansion of hospital infrastructure, combined with a rising burden of chronic diseases and aging populations, creates strong demand for scalable dialysis solutions, while local manufacturing and regional supply chains influence procurement decisions.

These regional distinctions have implications for clinical protocols, distribution partnerships, and service models. Companies and health systems must tailor engagement strategies to each region's mix of inpatient capacity, outpatient growth, regulatory environment, and sourcing realities. Cross-border learning can accelerate adoption of best practices, but regional adaptation is essential to account for differences in workforce, reimbursement, and infrastructure maturity. Consequently, regional strategic planning should prioritize flexible product portfolios, adaptive pricing models, and investments in training that accommodate local care delivery patterns.

Critical company-level insights revealing how product innovation, diagnostics, and integrated service models are reshaping competitive advantage in AKI treatment ecosystems

Competitive dynamics in acute kidney injury treatment reflect an ecosystem of device manufacturers, pharmaceutical suppliers, diagnostics developers, and service providers. Device makers are investing in improved biocompatible materials, automated monitoring functions, and interfaces that support integration with electronic health records, while suppliers of consumables focus on supply reliability, sterilization quality, and cost-efficiency. Pharmaceutical companies are concentrating on stewardship programs, nephroprotective agents in development, and formulations that simplify dosing in heterogeneous patient populations. Diagnostic developers are advancing actionable biomarkers and point-of-care assays that shorten the time to intervention and enable risk-stratified treatment pathways.

Across this landscape, strategic moves such as alliances with hospital systems, bundled service offerings, and extended warranties are common as companies seek to reduce total cost of ownership for providers. There is also notable activity in after-sales service, remote monitoring, and training programs to ensure devices deliver consistent performance in high-acuity environments. Competitive advantage increasingly depends on the ability to present an integrated value proposition that couples technology with clinical evidence, service reliability, and clear pathways for reimbursement and implementation within complex care settings.

Actionable recommendations for healthcare leaders and industry stakeholders to enhance supply chain resilience, accelerate diagnostics, and secure reimbursement pathways

Industry leaders should take decisive steps to protect continuity of care while advancing innovation. Prioritize strengthening supply chain resilience by diversifying suppliers, reviewing tariff classifications, and evaluating nearshoring options for critical components and consumables to reduce exposure to sudden trade policy shifts. Simultaneously, accelerate investments in diagnostics and predictive analytics that enable earlier intervention, as earlier detection frequently leads to less invasive treatment needs and better outcomes. Clinical teams and manufacturers should co-design training and implementation services to reduce barriers to adoption of newer modalities and to ensure consistent protocol adherence across sites.

Engage payers and health systems early to demonstrate real-world performance and to construct reimbursement pathways that reflect value over time rather than episodic cost. Invest in modular product designs and scalable service models that can be adapted across hospitals, specialty clinics, and ambulatory surgical centers to capture diversified demand. Finally, develop clear communication strategies about supply assurance and contingency planning to reassure procurement teams and clinicians during periods of policy-driven market uncertainty. These combined actions will position organizations to respond nimbly to shifting regulatory, commercial, and clinical conditions.

A rigorous methodological framework combining clinician interviews, literature synthesis, regulatory review, and scenario analysis to ensure robust insights

The research methodology underpinning this analysis combines a multi-pronged approach to ensure robustness and relevance. Primary research included structured interviews with clinicians, procurement leaders, and industry executives to capture real-world practice patterns, procurement constraints, and adoption barriers. Secondary research synthesized peer-reviewed clinical literature, guideline publications, device regulatory filings, and publicly available policy documents to map the evidence base and to identify recent shifts in practice. Data triangulation techniques were used to reconcile differences across sources and to validate emerging themes.

Analytical methods included scenario analysis to assess potential supply chain and policy outcomes, qualitative coding of interview transcripts to surface recurring operational challenges, and comparative assessments of modality features and workflows. Limitations are acknowledged: the analysis relies on available clinical studies and expert opinion, which may evolve as new trials and regulatory decisions are published. To mitigate these limitations, the research integrated diverse stakeholder perspectives and prioritized findings with multi-source corroboration to present actionable, evidence-aligned insights.

A concise conclusion synthesizing the strategic imperatives, cross-sector responsibilities, and operational priorities essential for advancing AKI care

In conclusion, acute kidney injury treatment is at an inflection point driven by technological advances, shifting care models, and heightened attention to supply chain and policy risks. The interplay between modalities such as continuous renal replacement therapy and evolving pharmacological and supportive care strategies requires coordinated responses from clinicians, manufacturers, and payers. Regional and segmentation nuances matter: different patient cohorts and care settings demand tailored solutions, and trade policy developments can materially affect procurement and availability of critical supplies. The organizations best positioned for success will be those that combine robust clinical evidence, resilient operations, and flexible commercial strategies.

Sustained progress will depend on cross-sector collaboration: clinicians adopting standardized pathways, manufacturers delivering integrated and service-oriented offerings, and health systems enabling reimbursement structures that recognize long-term value. By aligning innovation with pragmatic implementation plans and supply assurance measures, stakeholders can reduce the clinical and economic burden of acute kidney injury while improving patient outcomes across diverse care environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence algorithms for early detection of acute kidney injury in hospitalized patients
  • 5.2. Emergence of biomarker-guided personalized therapy protocols to reduce acute kidney injury risk in surgery patients
  • 5.3. Shift toward point-of-care diagnostic devices for rapid renal function assessment in critical care settings
  • 5.4. Development of novel renal replacement therapies with enhanced biocompatibility and reduced complications in ICU care
  • 5.5. Rising investment in cell-based regenerative medicine approaches targeting kidney injury repair mechanisms post-transplantation
  • 5.6. Expansion of telemedicine-enabled patient monitoring platforms for early intervention in acute kidney injury management
  • 5.7. Growing adoption of SGLT2 inhibitors for nephroprotection and acute kidney injury prevention in diabetic patients
  • 5.8. Regulatory acceleration through breakthrough therapy designations for innovative AKI treatment candidates by FDA and EMA

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Kidney Injury Treatment Market, by Treatment Type

  • 8.1. Dialysis
    • 8.1.1. Continuous Renal Replacement Therapy (CRRT)
    • 8.1.2. Intermittent Hemodialysis
    • 8.1.3. Sustained Low-Efficiency Dialysis (SLED)
  • 8.2. Pharmacological Treatment
    • 8.2.1. Antibiotics
    • 8.2.2. Diuretics
    • 8.2.3. Pain Management Drugs
    • 8.2.4. Rehydration Drugs
  • 8.3. Supportive Care
    • 8.3.1. Dietary Management
    • 8.3.2. Fluid Management

9. Acute Kidney Injury Treatment Market, by AKI Type

  • 9.1. Intrinsic Renal Acute Kidney Injury
  • 9.2. Post-renal Acute Kidney Injury
  • 9.3. Pre-renal Acute Kidney Injury

10. Acute Kidney Injury Treatment Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Acute Kidney Injury Treatment Market, by Patient Demographics

  • 11.1. Adult Patients
  • 11.2. Geriatric Patients
  • 11.3. Pediatric Patients

12. Acute Kidney Injury Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Acute Kidney Injury Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Acute Kidney Injury Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Alloksys Life Sciences B.V.
    • 15.3.3. Amgen Inc.
    • 15.3.4. Asahi Kasei Medical Co., Ltd.
    • 15.3.5. Astellas Pharma Inc.
    • 15.3.6. B. Braun Melsungen AG
    • 15.3.7. Baxter International, Inc.
    • 15.3.8. Bayer AG
    • 15.3.9. bioMerieux SA
    • 15.3.10. CardioRenal Systems, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ACUTE KIDNEY INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ACUTE KIDNEY INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ACUTE KIDNEY INJURY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN ACUTE KIDNEY